Edition:
United Kingdom

Xenon Pharmaceuticals Inc (XENE.OQ)

XENE.OQ on NASDAQ Stock Exchange Global Market

2.40USD
14 Dec 2017
Change (% chg)

$-0.15 (-5.88%)
Prev Close
$2.55
Open
$2.50
Day's High
$2.50
Day's Low
$2.40
Volume
7,543
Avg. Vol
11,203
52-wk High
$9.90
52-wk Low
$2.15

Latest Key Developments (Source: Significant Developments)

Xenon Pharmaceuticals reports Q3 loss per share $0.43
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Xenon Pharmaceuticals Inc :Xenon Pharmaceuticals reports third quarter 2017 financial results and provides corporate update.Q3 revenue $300,000 versus $400,000.Xenon Pharmaceuticals Inc - qtrly loss per share $0.43.  Full Article

Xenon Pharma announces initiation of XEN1101 phase 1 clinical trial
Tuesday, 17 Oct 2017 

Oct 17 (Reuters) - Xenon Pharmaceuticals Inc :Xenon Pharmaceuticals announces initiation of XEN1101 phase 1 clinical trial.XEN1101 phase 2 proof-of-concept clinical trial anticipated to begin in Q3 2018​.Expect to file an IND equivalent application in Q4 of this year for XEN901​.  Full Article

Xenon Pharmaceuticals reports Q2 revenue $400,000 versus $4.0 million
Wednesday, 3 Aug 2016 

Xenon Pharmaceuticals Inc : Xenon pharmaceuticals reports second quarter 2016 financial results and provides corporate update .Q2 revenue $400,000 versus $4.0 million.  Full Article

Xenon Pharmaceuticals Q1 revenue $600,000 vs $4.0 mln
Tuesday, 10 May 2016 

Xenon Pharmaceuticals Inc : Xenon Pharmaceuticals Inc says net loss for quarter ended march 31, 2016 was $3.3 million, compared to net loss of $9.2 million for same period in 2015 . Xenon Pharmaceuticals reports first quarter 2016 financial results and provides corporate update .Q1 revenue $600,000 versus $4.0 million.  Full Article

Xenon Pharmaceuticals Inc says initiated phase 2 trial of XEN801 in moderate to severe acne
Tuesday, 8 Mar 2016 

Xenon Pharmaceuticals Inc:Reports 2015 financial results and provides corporate update.Says initiated phase 2 trial of xen801 in moderate to severe acne; results anticipated in fourth quarter of 2016.  Full Article

Xenon Pharma initiates phase 2 clinical trial of XEN801 to treat moderate to severe acne
Wednesday, 10 Feb 2016 

Xenon Pharmaceuticals Inc:Says it has commenced dosing patients in a Phase 2 clinical trial of XEN801.Expects to enroll approximately 150 patients with acne at multiple sites, with topline results expected in the fourth quarter of 2016.  Full Article

BRIEF-Xenon Pharmaceuticals reports Q3 loss per share $0.43

* Xenon Pharmaceuticals reports third quarter 2017 financial results and provides corporate update